Flinders University Sleep Apnoea Drug Breakthrough Poised for US Approval

A groundbreaking development from Flinders University researchers is transforming the landscape of obstructive sleep apnoea (OSA) treatment in Australia and potentially worldwide. Pioneering pharmacotherapy approaches are offering a pill-based alternative to traditional continuous positive airway pressure (CPAP) machines, with one promising combination drug on the cusp of US Food and Drug Administration (FDA) approval. This innovation stems from years of dedicated work at Flinders' FHMRI Sleep Health group, led by Professor Danny Eckert, addressing a condition that affects over one million Australians and costs the nation more than $5 billion annually in healthcare and productivity losses.

Understanding Obstructive Sleep Apnoea and Its Toll

Obstructive sleep apnoea occurs when throat muscles intermittently relax and block the airway during sleep, causing repeated breathing pauses. These events, measured as the apnoea-hypopnoea index (AHI), lead to oxygen drops, fragmented sleep, and daytime fatigue. Untreated OSA heightens risks for cardiovascular disease, diabetes, stroke, and road accidents—equivalent to drunk driving in impairment levels.

In Australia, prevalence is around 20-30% in middle-aged adults, rising with obesity. Standard CPAP therapy delivers air pressure via a mask but sees only 50% long-term adherence due to discomfort. Flinders researchers have shifted focus to the underlying physiology: non-anatomical traits like low arousal threshold and poor upper airway muscle responsiveness during sleep.

Flinders University's Leadership in Sleep Research

Located in Adelaide, South Australia, Flinders University's FHMRI Sleep Health (formerly Adelaide Institute for Sleep Health) boasts a state-of-the-art 900sqm facility with advanced polysomnography labs, driver simulators, and virtual reality setups. Over 60 experts collaborate on transdisciplinary projects, from biomarkers to health services models.

Professor Danny Eckert, NHMRC Leadership Fellow and Mathew Flinders Professor, drives precision medicine for OSA. His team phenotypically stratifies patients—identifying those with arousal issues or muscle dilator problems—to tailor therapies. This trait-based framework has spurred global interest, positioning Flinders as a hub for non-CPAP innovations.

The Breakthrough Pharmacotherapy: Combo Drugs Targeting Physiology

Flinders' hallmark is repurposing existing medications into targeted combos. A landmark 2022 double-blind trial tested reboxetine (a norepinephrine reuptake inhibitor used for depression) alone and with oxybutynin. In 16 OSA patients, reboxetine reduced AHI by stabilising breathing and boosting oxygen levels, without oxybutynin's added benefit. Published in the Journal of Clinical Sleep Medicine, it proved norepinephrine modulation strengthens airway muscles during sleep. Read the full study here.

Building on this, collaborations with Apnimed yielded AD109 (atomoxetine + aroxybutynin), a dual-action pill addressing arousal threshold and dilator muscle responsiveness. Phase 3 trials (LunAIRo, 2025) showed robust AHI reductions across mild-to-severe OSA and body weights. Positive topline results position AD109 for FDA submission, with approval anticipated in 2027—directly informed by Flinders' foundational research.

Clinical Trial Results and Safety Profile

Flinders-led trials demonstrate 30-50% AHI reductions with combo drugs, comparable to surgery in select patients. Unlike tirzepatide (Zepbound, FDA-approved 2024 for obese OSA), which primarily aids via weight loss, Flinders' approach targets non-obese mechanisms, broadening applicability.

• AHI Reduction: Reboxetine: ~25-30%; AD109: up to 50% in responders.
• Oxygen Improvement: Stable SpO2 during events.
• Safety: Mild side effects (dry mouth, tachycardia); no serious adverse events in trials.
• Responder Rate: 60-70%, identified via arousal threshold phenotyping.

These outcomes rival CPAP's efficacy but with superior tolerability—no mask required.

Path to US Approval and Global Rollout

Apnimed's AD109 leverages Flinders' phenotyping to refine patient selection, accelerating FDA review. Eckert's publications in NEJM and Lancet Respiratory Medicine underpin regulatory dossiers. Approval could launch in 2027, followed by Australian Therapeutic Goods Administration (TGA) nod. Flinders anticipates local trials for AD173 (next-gen combo) soon. Apnimed phase 3 results.

Implications for Australian Healthcare

For Australia's overburdened sleep clinics, pharmacotherapy means scalable, home-based care. Rural patients gain access without CPAP fittings. Economic modelling projects $1-2B savings via reduced cardiovascular admissions. Flinders' primary care models integrate screening via GPs, enhancing equity.

Stakeholders praise: Eckert notes, "Our goal is more choices and better outcomes." Patient advocates highlight empowerment for CPAP dropouts.

Complementary Innovations: Beyond Pills

Flinders advances multi-modal options. A 2026 CHEST study (DOI link) introduced percutaneous hypoglossal nerve stimulation (HNS): ultrasound-guided electrodes activate tongue muscles in 90 minutes, yielding 93% airflow improvement vs CPAP. Led by Dr Amal Osman, it suits CPAP-intolerant patients.

Nasal sprays stabilising airways and VR training round out the portfolio, showcasing Flinders' holistic pipeline.

Challenges and Future Directions

Phenotyping costs and responder identification remain hurdles; AI integration looms. Long-term data needed for cardiovascular outcomes. Eckert's team eyes combos with weight-loss agents for obese patients.

Photo by Laura Chouette on Unsplash

• Precision trials for arousal vs muscle phenotypes.
• Paediatric extensions.
• Global partnerships for Phase 4 post-approval studies.

Careers and Training in Sleep Research at Australian Universities

Flinders exemplifies higher education's role, training PhDs and postdocs in phenotyping, trials, and translation. Opportunities abound in pharmacology, physiology, and data science. Collaborations with Harvard and Woolcock foster international mobility. Aspiring researchers can pursue /research-jobs at Flinders via AcademicJobs.com.au.

This breakthrough underscores universities' vital contributions to health innovation, promising better lives for millions.